Details for Patent: RE50453
✉ Email this page to a colleague
Which drugs does patent RE50453 protect, and when does it expire?
Patent RE50453 protects TRIKAFTA (COPACKAGED), ALYFTREK, and SYMDEKO (COPACKAGED), and is included in four NDAs.
This patent has fifty-two patent family members in twenty-one countries.
Summary for Patent: RE50453
| Title: | Indole derivatives as CFTR modulators |
| Abstract: | Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. |
| Inventor(s): | Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Djamel Numa, Xiaoqing Yang |
| Assignee: | Vertex Pharmaceuticals Inc |
| Application Number: | US18/089,898 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent RE50453
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULE;ORAL | 217660-001 | Apr 26, 2023 | RX | Yes | No | RE50453 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULE;ORAL | 217660-002 | Apr 26, 2023 | RX | Yes | Yes | RE50453 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Vertex Pharms Inc | ALYFTREK | deutivacaftor; tezacaftor; vanzacaftor calcium | TABLET;ORAL | 218730-001 | Dec 20, 2024 | RX | Yes | No | RE50453 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE50453
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2007235260 | ⤷ Start Trial | |||
| Brazil | PI0710965 | ⤷ Start Trial | |||
| Canada | 2648719 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
